Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas

V. H C Bramwell, H. T. Mouridsen, A. Santoro, G. Blackledge, R. Somers, J. Verweij, P. Dombernowsky, M. Onsrud, D. Thomas, R. Sylvester, A. Van Oosterom

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1.5 g/m2) in a randomized phase II study. Both drugs were given by 24-h intravenous (i.v.) infusion every 3 weeks along with i.v. bolus infusions of mesna (400 mg/m2), which was given every 4 h for nine administrations. Eligibility criteria included an age of 15-75 years, biopsy-proven advanced metastatic soft-tissue sarcoma, and a World Health Organization performance status of 0-2. Exclusion criteria were prior treatment with classic alkylating agents, a creatinine level of >150 μmol/l, a bilirubin level of >20 μmol/l, a leukocyte cell count of 9/l, and a platelet count of 9/l. A total of 171 patients were entered, 24 of whom were ineligible and 12, inevaluable, leaving 135 patients evaluable. In all, 67 patients were treated with cyclophosphamide, and the overall response rate was 7.5%. All responders to cyclophosphamide were patients who had not received prior chemotherapy (13% of 38 patients). Another 68 patients were given ifosfamide, 18% of whom responded to treatment. Of the 28 ifosfamide-treated patients who had received prior chemotherapy, 7% were responders. The response rate for the remaining 40 patients was 25%. The higher overall response rate (P = 0.13) obtained with less myelosuppression in ifosfamide-treated patients suggests that this agent may have advantages over cyclophosphamide in combination therapy.

Original languageEnglish
JournalCancer Chemotherapy and Pharmacology
Volume31
Issue numberSUPPL. 2
Publication statusPublished - 1993

Fingerprint

Ifosfamide
Sarcoma
Cyclophosphamide
Tissue
Chemotherapy
Mesna
Biopsy
Alkylating Agents
Platelets
Bilirubin
Intravenous Infusions
Creatinine
Health
Drug Therapy
Proxy
Platelet Count
Leukocyte Count
Pharmaceutical Preparations
Therapeutics
Cell Count

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Bramwell, V. H. C., Mouridsen, H. T., Santoro, A., Blackledge, G., Somers, R., Verweij, J., ... Van Oosterom, A. (1993). Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas. Cancer Chemotherapy and Pharmacology, 31(SUPPL. 2).

Cyclophosphamide versus ifosfamide : A randomized phase II trial in adult soft-tissue sarcomas. / Bramwell, V. H C; Mouridsen, H. T.; Santoro, A.; Blackledge, G.; Somers, R.; Verweij, J.; Dombernowsky, P.; Onsrud, M.; Thomas, D.; Sylvester, R.; Van Oosterom, A.

In: Cancer Chemotherapy and Pharmacology, Vol. 31, No. SUPPL. 2, 1993.

Research output: Contribution to journalArticle

Bramwell, VHC, Mouridsen, HT, Santoro, A, Blackledge, G, Somers, R, Verweij, J, Dombernowsky, P, Onsrud, M, Thomas, D, Sylvester, R & Van Oosterom, A 1993, 'Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas', Cancer Chemotherapy and Pharmacology, vol. 31, no. SUPPL. 2.
Bramwell, V. H C ; Mouridsen, H. T. ; Santoro, A. ; Blackledge, G. ; Somers, R. ; Verweij, J. ; Dombernowsky, P. ; Onsrud, M. ; Thomas, D. ; Sylvester, R. ; Van Oosterom, A. / Cyclophosphamide versus ifosfamide : A randomized phase II trial in adult soft-tissue sarcomas. In: Cancer Chemotherapy and Pharmacology. 1993 ; Vol. 31, No. SUPPL. 2.
@article{5e4493946dff44d2aeb3563e18ca39b6,
title = "Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas",
abstract = "Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1.5 g/m2) in a randomized phase II study. Both drugs were given by 24-h intravenous (i.v.) infusion every 3 weeks along with i.v. bolus infusions of mesna (400 mg/m2), which was given every 4 h for nine administrations. Eligibility criteria included an age of 15-75 years, biopsy-proven advanced metastatic soft-tissue sarcoma, and a World Health Organization performance status of 0-2. Exclusion criteria were prior treatment with classic alkylating agents, a creatinine level of >150 μmol/l, a bilirubin level of >20 μmol/l, a leukocyte cell count of 9/l, and a platelet count of 9/l. A total of 171 patients were entered, 24 of whom were ineligible and 12, inevaluable, leaving 135 patients evaluable. In all, 67 patients were treated with cyclophosphamide, and the overall response rate was 7.5{\%}. All responders to cyclophosphamide were patients who had not received prior chemotherapy (13{\%} of 38 patients). Another 68 patients were given ifosfamide, 18{\%} of whom responded to treatment. Of the 28 ifosfamide-treated patients who had received prior chemotherapy, 7{\%} were responders. The response rate for the remaining 40 patients was 25{\%}. The higher overall response rate (P = 0.13) obtained with less myelosuppression in ifosfamide-treated patients suggests that this agent may have advantages over cyclophosphamide in combination therapy.",
author = "Bramwell, {V. H C} and Mouridsen, {H. T.} and A. Santoro and G. Blackledge and R. Somers and J. Verweij and P. Dombernowsky and M. Onsrud and D. Thomas and R. Sylvester and {Van Oosterom}, A.",
year = "1993",
language = "English",
volume = "31",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Cyclophosphamide versus ifosfamide

T2 - A randomized phase II trial in adult soft-tissue sarcomas

AU - Bramwell, V. H C

AU - Mouridsen, H. T.

AU - Santoro, A.

AU - Blackledge, G.

AU - Somers, R.

AU - Verweij, J.

AU - Dombernowsky, P.

AU - Onsrud, M.

AU - Thomas, D.

AU - Sylvester, R.

AU - Van Oosterom, A.

PY - 1993

Y1 - 1993

N2 - Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1.5 g/m2) in a randomized phase II study. Both drugs were given by 24-h intravenous (i.v.) infusion every 3 weeks along with i.v. bolus infusions of mesna (400 mg/m2), which was given every 4 h for nine administrations. Eligibility criteria included an age of 15-75 years, biopsy-proven advanced metastatic soft-tissue sarcoma, and a World Health Organization performance status of 0-2. Exclusion criteria were prior treatment with classic alkylating agents, a creatinine level of >150 μmol/l, a bilirubin level of >20 μmol/l, a leukocyte cell count of 9/l, and a platelet count of 9/l. A total of 171 patients were entered, 24 of whom were ineligible and 12, inevaluable, leaving 135 patients evaluable. In all, 67 patients were treated with cyclophosphamide, and the overall response rate was 7.5%. All responders to cyclophosphamide were patients who had not received prior chemotherapy (13% of 38 patients). Another 68 patients were given ifosfamide, 18% of whom responded to treatment. Of the 28 ifosfamide-treated patients who had received prior chemotherapy, 7% were responders. The response rate for the remaining 40 patients was 25%. The higher overall response rate (P = 0.13) obtained with less myelosuppression in ifosfamide-treated patients suggests that this agent may have advantages over cyclophosphamide in combination therapy.

AB - Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1.5 g/m2) in a randomized phase II study. Both drugs were given by 24-h intravenous (i.v.) infusion every 3 weeks along with i.v. bolus infusions of mesna (400 mg/m2), which was given every 4 h for nine administrations. Eligibility criteria included an age of 15-75 years, biopsy-proven advanced metastatic soft-tissue sarcoma, and a World Health Organization performance status of 0-2. Exclusion criteria were prior treatment with classic alkylating agents, a creatinine level of >150 μmol/l, a bilirubin level of >20 μmol/l, a leukocyte cell count of 9/l, and a platelet count of 9/l. A total of 171 patients were entered, 24 of whom were ineligible and 12, inevaluable, leaving 135 patients evaluable. In all, 67 patients were treated with cyclophosphamide, and the overall response rate was 7.5%. All responders to cyclophosphamide were patients who had not received prior chemotherapy (13% of 38 patients). Another 68 patients were given ifosfamide, 18% of whom responded to treatment. Of the 28 ifosfamide-treated patients who had received prior chemotherapy, 7% were responders. The response rate for the remaining 40 patients was 25%. The higher overall response rate (P = 0.13) obtained with less myelosuppression in ifosfamide-treated patients suggests that this agent may have advantages over cyclophosphamide in combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027533415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027533415&partnerID=8YFLogxK

M3 - Article

C2 - 8453694

AN - SCOPUS:0027533415

VL - 31

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - SUPPL. 2

ER -